Isofol, a clinical stage pharmaceutical company based in Gothenburg, Sweden, has launched a global program to identify one or more strategic partners for commercialization of its Modufolin(R) chemotherapy asset.
The Sage Group, which is based in Europe, the USA and Asia, has been appointed by Isofol to assist the company. Sage’s job is to identify a well-established pharmaceutical partner who will work with the company to promote the value of Modufolin(R).
Jan-Eric Osterlund, executive chairman of Isofol, said, “We are delighted to be working with The Sage Group, who are providing us with access to a global network of potential partners for Modufolin(R). We are conducting two Phase 1/2
clinical trials with Modufolin(R) in colorectal cancer and in osteosarcoma and intend to work with a strategic partner on these and future trials.”